The oral Janus kinase (JAK) 1/2 inhibitor baricitinib (Olumiant) demonstrated significantly better efficacy than cyclophosphamide infusions in the treatment of lupus nephritis in a small, independently funded, phase 3, double-blind clinical trial , Manal Hassanien, MD, reported at the European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Meeting.

Baricitinib, ...